vs
Idexx Laboratories（IDXX）与Steris（STE）财务数据对比。点击上方公司名可切换其他公司
Steris的季度营收约是Idexx Laboratories的1.4倍（$1.5B vs $1.1B），Idexx Laboratories净利率更高（22.8% vs 12.9%，领先9.9%），Idexx Laboratories同比增速更快（14.3% vs 9.2%），Idexx Laboratories自由现金流更多（$326.3M vs $199.5M），过去两年Steris的营收复合增速更高（15.8% vs 6.4%）
IDEXX Laboratories是1983年成立的美国跨国企业，主营伴侣动物诊疗、畜禽养殖、水质检测、乳制品领域相关产品与服务的研发、生产及分销，总部位于缅因州韦斯特布鲁克，欧洲、中东及非洲地区分部设于荷兰霍夫多普。
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
IDXX vs STE — 直观对比
营收规模更大
STE
是对方的1.4倍
$1.1B
营收增速更快
IDXX
高出5.1%
9.2%
净利率更高
IDXX
高出9.9%
12.9%
自由现金流更多
IDXX
多$126.8M
$199.5M
两年增速更快
STE
近两年复合增速
6.4%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.5B |
| 净利润 | $248.2M | $192.9M |
| 毛利率 | 60.3% | 43.8% |
| 营业利润率 | 28.9% | 18.3% |
| 净利率 | 22.8% | 12.9% |
| 营收同比 | 14.3% | 9.2% |
| 净利润同比 | 14.8% | 11.2% |
| 每股收益（稀释后） | $3.09 | $1.96 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IDXXSTE
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.5B | ||
| Q2 25 | $1.1B | $1.4B | ||
| Q1 25 | $998.4M | $1.5B | ||
| Q4 24 | $954.3M | $1.4B | ||
| Q3 24 | $975.5M | $1.3B | ||
| Q2 24 | $1.0B | $1.3B | ||
| Q1 24 | $964.1M | $1.1B |
净利润IDXXSTE
| Q4 25 | $248.2M | $192.9M | ||
| Q3 25 | $274.6M | $191.9M | ||
| Q2 25 | $294.0M | $177.4M | ||
| Q1 25 | $242.7M | $145.7M | ||
| Q4 24 | $216.1M | $173.5M | ||
| Q3 24 | $232.8M | $150.0M | ||
| Q2 24 | $203.3M | $145.4M | ||
| Q1 24 | $235.6M | $-1.4M |
毛利率IDXXSTE
| Q4 25 | 60.3% | 43.8% | ||
| Q3 25 | 61.8% | 44.2% | ||
| Q2 25 | 62.6% | 45.1% | ||
| Q1 25 | 62.4% | 43.3% | ||
| Q4 24 | 59.8% | 44.5% | ||
| Q3 24 | 61.1% | 43.6% | ||
| Q2 24 | 61.7% | 44.7% | ||
| Q1 24 | 61.5% | 40.2% |
营业利润率IDXXSTE
| Q4 25 | 28.9% | 18.3% | ||
| Q3 25 | 32.1% | 18.2% | ||
| Q2 25 | 33.6% | 17.7% | ||
| Q1 25 | 31.7% | 14.6% | ||
| Q4 24 | 27.4% | 17.9% | ||
| Q3 24 | 31.2% | 16.5% | ||
| Q2 24 | 26.3% | 14.5% | ||
| Q1 24 | 31.0% | 22.0% |
净利率IDXXSTE
| Q4 25 | 22.8% | 12.9% | ||
| Q3 25 | 24.8% | 13.1% | ||
| Q2 25 | 26.5% | 12.8% | ||
| Q1 25 | 24.3% | 9.8% | ||
| Q4 24 | 22.7% | 12.7% | ||
| Q3 24 | 23.9% | 11.3% | ||
| Q2 24 | 20.3% | 11.4% | ||
| Q1 24 | 24.4% | -0.1% |
每股收益（稀释后）IDXXSTE
| Q4 25 | $3.09 | $1.96 | ||
| Q3 25 | $3.40 | $1.94 | ||
| Q2 25 | $3.63 | $1.79 | ||
| Q1 25 | $2.96 | $1.48 | ||
| Q4 24 | $2.62 | $1.75 | ||
| Q3 24 | $2.80 | $1.51 | ||
| Q2 24 | $2.44 | $1.46 | ||
| Q1 24 | $2.81 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.1M | $423.7M |
| 总债务越低越好 | $450.0M | $1.9B |
| 股东权益账面价值 | $1.6B | $7.2B |
| 总资产 | $3.4B | $10.6B |
| 负债/权益比越低杠杆越低 | 0.28× | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资IDXXSTE
| Q4 25 | $180.1M | $423.7M | ||
| Q3 25 | $208.2M | $319.2M | ||
| Q2 25 | $164.6M | $279.7M | ||
| Q1 25 | $164.0M | $171.7M | ||
| Q4 24 | $288.3M | $155.2M | ||
| Q3 24 | $308.6M | $172.2M | ||
| Q2 24 | $401.6M | $198.3M | ||
| Q1 24 | $397.4M | $207.0M |
总债务IDXXSTE
| Q4 25 | $450.0M | $1.9B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | $617.8M | $2.0B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $3.1B |
股东权益IDXXSTE
| Q4 25 | $1.6B | $7.2B | ||
| Q3 25 | $1.6B | $7.0B | ||
| Q2 25 | $1.5B | $7.0B | ||
| Q1 25 | $1.4B | $6.6B | ||
| Q4 24 | $1.6B | $6.4B | ||
| Q3 24 | $1.6B | $6.6B | ||
| Q2 24 | $1.6B | $6.4B | ||
| Q1 24 | $1.6B | $6.3B |
总资产IDXXSTE
| Q4 25 | $3.4B | $10.6B | ||
| Q3 25 | $3.4B | $10.4B | ||
| Q2 25 | $3.3B | $10.4B | ||
| Q1 25 | $3.2B | $10.1B | ||
| Q4 24 | $3.3B | $10.0B | ||
| Q3 24 | $3.4B | $10.2B | ||
| Q2 24 | $3.4B | $10.1B | ||
| Q1 24 | $3.4B | $11.1B |
负债/权益比IDXXSTE
| Q4 25 | 0.28× | 0.27× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | 0.39× | 0.32× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.35× | ||
| Q1 24 | — | 0.50× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $355.8M | $298.2M |
| 自由现金流经营现金流 - 资本支出 | $326.3M | $199.5M |
| 自由现金流率自由现金流/营收 | 29.9% | 13.3% |
| 资本支出强度资本支出/营收 | 2.7% | 6.6% |
| 现金转化率经营现金流/净利润 | 1.43× | 1.55× |
| 过去12个月自由现金流最近4个季度 | $1.1B | $917.1M |
8季度趋势，按日历期对齐
经营现金流IDXXSTE
| Q4 25 | $355.8M | $298.2M | ||
| Q3 25 | $402.3M | $287.8M | ||
| Q2 25 | $185.7M | $420.0M | ||
| Q1 25 | $238.0M | $260.8M | ||
| Q4 24 | $262.0M | $332.8M | ||
| Q3 24 | $220.1M | $250.7M | ||
| Q2 24 | $248.3M | $303.7M | ||
| Q1 24 | $198.6M | $254.8M |
自由现金流IDXXSTE
| Q4 25 | $326.3M | $199.5M | ||
| Q3 25 | $371.2M | $201.3M | ||
| Q2 25 | $151.6M | $326.4M | ||
| Q1 25 | $207.9M | $189.9M | ||
| Q4 24 | $232.8M | $243.6M | ||
| Q3 24 | $192.0M | $148.8M | ||
| Q2 24 | $215.0M | $195.7M | ||
| Q1 24 | $168.3M | $163.3M |
自由现金流率IDXXSTE
| Q4 25 | 29.9% | 13.3% | ||
| Q3 25 | 33.6% | 13.8% | ||
| Q2 25 | 13.7% | 23.5% | ||
| Q1 25 | 20.8% | 12.8% | ||
| Q4 24 | 24.4% | 17.8% | ||
| Q3 24 | 19.7% | 11.2% | ||
| Q2 24 | 21.4% | 15.3% | ||
| Q1 24 | 17.5% | 14.6% |
资本支出强度IDXXSTE
| Q4 25 | 2.7% | 6.6% | ||
| Q3 25 | 2.8% | 5.9% | ||
| Q2 25 | 3.1% | 6.7% | ||
| Q1 25 | 3.0% | 4.8% | ||
| Q4 24 | 3.1% | 6.5% | ||
| Q3 24 | 2.9% | 7.7% | ||
| Q2 24 | 3.3% | 8.4% | ||
| Q1 24 | 3.1% | 8.2% |
现金转化率IDXXSTE
| Q4 25 | 1.43× | 1.55× | ||
| Q3 25 | 1.47× | 1.50× | ||
| Q2 25 | 0.63× | 2.37× | ||
| Q1 25 | 0.98× | 1.79× | ||
| Q4 24 | 1.21× | 1.92× | ||
| Q3 24 | 0.95× | 1.67× | ||
| Q2 24 | 1.22× | 2.09× | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
